Tokai Pharmaceuticals Inks $23M
Tokai Pharmaceuticals, a biopharmaceutical company focused on treatment for prostate cancer, has closed a $23 million Series D3 financing round. The money will support clinical development of the company’s lead drug candidate. Existing shareholders Novartis Venture Fund and Apple Tree Partners provided the financing. Tokai is based in Cambridge, Mass.
20 September 2011•4 mins read
